Sue J Sohn

Title: Sue J Sohn: Innovator in Immunotherapy

Introduction

Sue J Sohn is a prominent inventor based in Daly City, California. She has made significant contributions to the field of immunotherapy, particularly through her innovative research and development of binding proteins.

Latest Patents

Sue J Sohn holds a patent related to the blockade of TIGIT and CD112R. The patent details the provision of TIGIT binding proteins, CD112R binding proteins, and their combinations. It also includes compositions that comprise these binding proteins, optionally further including PD-1 binding proteins. Additionally, the patent covers related conjugates, fusion proteins, nucleic acids, vectors, host cells, and kits. Furthermore, it outlines pharmaceutical compositions that incorporate these binding proteins and methods for treating subjects in need.

Career Highlights

Sue J Sohn is currently associated with Amgen Inc., a leading biotechnology company. Her work focuses on advancing therapeutic strategies that target immune checkpoints, which are crucial for developing effective cancer treatments.

Collaborations

Some of her notable coworkers include Marissa Mock and Ian Nevin Foltz, who contribute to the collaborative efforts in her research endeavors.

Conclusion

Sue J Sohn's innovative work in the field of immunotherapy exemplifies the impact of scientific research on healthcare. Her contributions continue to pave the way for new treatment options for patients in need.